Journal of Modern OncologyJournal of Modern OncologyСовременная онкология1815-14341815-1442LLC Obyedinennaya Redaktsiya26884ArticlesСтатьиResearch ArticleCUP-syndrome: the present view of the problem (a review of literature)CUP-синдром: современный взгляд на проблему (обзор литературы)LevitskayaN VЛевицкаяНаталья Вячеславовна

докторант каф. онкологии

LewitzkiVЛевицкийВиктор

врач-онколог

KomarovI GКомаровИгорь Геннадьевич

д-р мед. наук, проф., вед. науч. сотр. хирургического отд-ния диагностики опухолей

NemtsovaM VНемцоваМарина Вячеславовна

д-р мед. наук, проф. каф. медицинской генетики

PoddubnayaI VПоддубнаяИрина Владимировна

д-р мед. наук, проф., член-корр РАМН, зав. каф. онкологии

ГБОУ ДПО РМАПО Минздрава РФ,МоскваUniversitätsklinikum Rostock Klinik, Rostock, Deutschland (Германия)ФГБУ РОНЦ им. Н.Н.Блохина15032013151NO1 (2013)ТОМ 15, №1 (2013)414509042020Copyright ©; 2013, Consilium MedicumCopyright ©; 2013, ООО "Консилиум Медикум"2013Consilium MedicumООО "Консилиум Медикум"https://creativecommons.org/licenses/by-nc/4.0https://modernonco.orscience.ru/1815-1434/article/view/26884

Tumors of unknown primary site (CUP-syndrome) – an intriguing clinical phenomenon that each year 5% of patients with newly diagnosed malignancies. The absence of clinical manifestations of the primary tumor, early development, unusual, often multiple metastases – signs of this heterogeneous group of neoplasms. However, there is no consensus whether the CUP-syndrome metastases undetected primary tumor or an independent biological phenomenon with certain genetic and phenotypic characteristics. Identification of major molecular abnormalities that characterize CUP-syndrome, slow progressive. Profile of gene expression and the expression of miRNAs are highly specific tests that can help to identify histogenesis of tumors without primary site.

Опухоли без выявленного первичного очага (CUP-синдром) – интригующий клинический феномен, который ежегодно регистрируется у 5% пациентов с вновь выявленными злокачественными новообразованиями. Отсутствие клинических проявлений первичной опухоли, развитие ранних, необычных, зачастую множественных метастазов – признаки этой гетерогенной группы новообразований. Однако не существует единого мнения, является ли CUP-синдром метастазами невыявленной первичной опухоли, или это самостоятельное биологическое явление с определенными генетическими и фенотипическими особенностями. Идентификация основных молекулярных отклонений, характеризующих CUP-синдром, медленно, но прогрессирует. Профиль генной экспрессии и экспрессии микро-РНК являются высокоспецифичными тестами, которые должны помочь определить гистогенез опухолей без выявленного первичного очага.

unknown primary tumoursCUP-syndromeопухоли без выявленного первичного очагаCUP-синдромКомаров И.Г., Комов Д.В. Метастазы злокачественных опухолей без выявленного первичного очага. Энциклопедия клинической онкологии. М.: РЛС, 2004.Минимальные клинические рекомендации Европейского общества медицинской онкологии. М., 2008.Abbruzzese J.L., Abbruzzese M.C., Hess K.R. Unknown primary carcinoma: natural history and prognostic factors in 657 consecutive patients. J Clin Oncol 1994; 12: 1272–80.Abeloff M.D., Armitage J.O., Lichter A.S. et al. Unknown primary in clinical oncology. Churchill Livingstone. NY 1995; p. 1833–45.Altman E, Cadman E. An analysis of 1539 patients with cancer of unknown primary site. Cancer 1986; 57 (1): 120–4.Bar-Eli M, Abbruzzese J.L., Lee-Jackson D et al. P53 gene mutation spectrum in human unknown primary tumors. Anticancer Res 1993; 13: 1619–23.Bloom G, Yang I.V., Boulware D et al. Multi - platform, multi - site, microarray - based human tumor classification. Am J Pathol 2004; 164: 9–16.Briasoulis E, Tsokos M et al. Bcl-2 and p53 protein expression in metastatic carcinoma of unknown primary origin. Biological and clinical implications. A Hellenic Cooperative Oncology Group study. Anticancer Res 1998; 18: 1907–14.Chevalier T.L., Cvitkovic E, Caille P. Early metastatic cancer of unknown primary origin at presentation. A clinical study of 302 consecutive autopsied patients. Arch Intern Med 1988; 148: 2035–9.Chorost M.I., Lee M.C., Yeoh C.B. Unknown primary. J Surg Oncol 2004; 87: 191–203.Culine S, Kramar A, Saghatchian M et al. Development and validation of a prognostic model to predict the length of survival in patients with carcinomas of an unknown primary site. J Clin Oncol 2002; 20 (24): 4679–83.Gaast A, Verweij J, Planting A.S. et al. Fluorouracil, doxorubicin and mitomycin C: (FAM) combination chemotherapy for metastatic adenocarcinoma of unknown primary. Eur J Cancer Clin Oncol 1988; 24 (4): 765–8.Greco F.A., Hainsworth J.D. Tumors of unknown origin. Cancer J Clin 1992; 42: 96–115.Greco F.A. Cancer of unknown primary site: evolving understanding and management of patients. Clin Advanc Hematol Oncol 2012; 10 (8): 518–24.Haldar S, Basu A, Croce C.M. Bcl-2 is the guardian of microtubule integrity. Cancer Res 1997; 57: 229–33.Hillen H.F. Unknown primary tumours review. Postgrad Med J 2000; 76: 690–3.Hollstein M, Sidransky D, Vogelstein B. P53 mutations in human cancers. Science 1991; 253: 49–53.Ilson D.H., Motzer R.J., Rodriguez E et al. Genetic analysis in the diagnosis of neoplasms of unknown primary tumor site. Semin Oncol 1993; 20: 229–37.Kirsten F, Chi C.H., Leary J.A. Metastatic adeno or undifferentiated carcinoma from unknown primary site – natural history and guidelines for identification of treatable subsets. Q J Med 1987; 62: 143–61.Krämer A, Gattenlöhner S, Neben K. CUP-Syndrom. Molekulare pathogenese und biologie pathologe 2009; 30: 117–24.Lembersky B.C., Thomas L.C. Metastases of unknown primary site. Med Clin North Am 1996; 80 (1): 153–71.Leonard R.J., Nystrom J.S. Diagnostic evaluation of patients with carcinoma of unknown primary site. Semin Oncol 1993; 20: 244–50.Levi F, Te V.C. et al. Epidemiology of unknown primary tumour. Eur J Cancer 2002; 38: 1890–12.Moll R. Initial CUP-Situation und CUP-Syndrom Pathologische Diagnostik. Pathologe 2009; 30 (Suppl. 2): 161–7.Motzer R.J., Rodriguez E, Reuter V.E. et al. Molecular and cytogenetic studies in the diagnosis of patients with poorly differentiated carcinomas of unknown primary site. J Clin Oncol 1995; 13: 274–82.Nissenblatt M.J. Carcinoma with unknown primary tumor (CUP syndrome). South Med J 1981; 74: 1497–502.Nystrom J.S., Weiner J.M., Heffelfinger-Juttner J. Metastatic and histologic presentation in unknown primary cancer. Semin Oncol 1997; 4: 53–8.Pantou D, Tsarouha H, Papadopoulou A. Cytogenetic profile of unknown primary tumors: clues for their pathogenesis and clinical management. Neoplasia 2003; 5: 23–31.Pavlidis N, Briasoulis E, Hainsworth J. Diagnostic and therapeutic management of cancer of an unknown primary. Eur J Cancer 2003; 39: 1990–2005.Pavlidis N. Forty years experience of treating cancer of unknown primary. Acta Oncol 2007; 46: 592–601.Pavlidis N, Wick M.R. Metastatic carcinomas of unknown primary origin. Chemotherapy NY. Demos Medical Publishing 2008; p. 225–34.Pavlidis N, Fizazi K. Carcinoma of unknown primary (CUP) critical reviews. Oncol Hematol 2009; 69: 271–8.Pavlidis N, Pentheroudakis G. Cancer of unknown primary site:questions to be answered. Ann Oncol 2010; 21 (7): 303–7.Pavlidis N, Pentheroudakis G. Cancer of unknown primary site. Lancet 2012; 379: 1428–5.Pentheroudakis G, Briasoulis E, Pavlidis N. Cancer of unknown primary site: missing primary or missing biology. Oncologist 2007; 12: 418–25.Petersen I, Hidalgo A, Petersen S. Chromosomal imbalances in brain metastases of solid tumors. Brain Pathol 2000; 10: 395–401.Rosenfeld N, Aharonov R, Meiri E et al. Micro RNAs accurately identify cancer tissue origin Nat Biotechnology 2008; 26: 462–9.Soong R, Robbins P.D., Dix B.R. et al. Concordance between p53 protein overexpression and gene mutation in a large series of common human carcinomas. Hum Pathol 1996; 27: 1050–5.Su A.I., Welsh J.B., Sapinoso L.M. et al. Molecular classification of human carcinomas by use of gene expression signatures. Cancer Res 2001; 61: 7388–93.Summersgill B, Goker H, Osin P et al. Establishing germ cell origin of undifferentiated tumors by identifying gain of 12p material using comparative genomic hybridization analysis of paraffin - embedded samples. Diagn Mol Pathol 1998; 7: 260–6.Tothill R.W., Kowalczyk A, Rischin D et al. An expression - based site of origin diagnostic method designed for clinical application to cancer of unknown origin. Cancer Res 2005; 65: 4031–40.Varadhachary G.R., Abbruzzese J.L., Lenz R. Diagnostic strategies for unknown primary cancer. Cancer 2004; 100: 1776–85.Visser O, Coebergh J.W., Schouten L.J. Incidence of cancer in the Netherlands. Netherlands Cancer Registry Utrecht 1993.Vousden K.H., Woude G.F. The ins and outs of p5. Nat Cell Biol 2000; p. 178–80.Wouw A.J., Janssen-Heijnen M.L., Coebergh J.W. Epidemiology of unknown primary tumours; incidence and population - based survival of 1285 patients in Southeast Netherlands 1984–1992. Eur J Cancer 2002; 3: 409–13.Wouw A.J., Jansen R.L., Speel E.J. The unknown biology of the unknown primary tumour: a literature review. Ann Oncol 2003; 14: 191–6.Wouw A.J., Jansen R.L., Griffioen A.W. Clinical and Immunohistochemical analysis of patients with unknown primary tumour. A search for prognostic factors in UPT. Anticancer Research 2004; 24: 297–302.